• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly forms neuroscience and immunology units amid leadership changes

August 17, 2021 By Sean Whooley

Eli LillyEli Lilly (NYSE:LLY) today announced executive leadership changes as it creates neuroscience and immunology business units.

Indianapolis-based Eli Lilly split its bio-medicines segment into Lilly Neuroscience and Lilly Immunology in the organizational shift, to be made effective Sept. 5, with Anne White set to lead the neuroscience unit and Patrik Jonsson set to head up the immunology arm.

White, currently SVP and president of Lilly Oncology, will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of its donanemab treatment for Alzheimer’s disease, which recently received FDA breakthrough device designation.

According to a news release, Jonsson’s role as president of Lilly Immunology will add to his ongoing responsibilities as SVP and president of Lilly USA and chief customer officer. He will lead the company’s launched products and Phase 3 portfolio of medicines in dermatology, gastroenterology and rheumatology.

Jacob Van Naarden, currently the CEO of Loxo Oncology at Lilly, was promoted to SVP, CEO of Loxo Oncology at Lilly and president of Lilly Oncology. He will be tasked with unifying the organizations and will also join Lilly’s executive committee.

Additionally, Alfonso Zulueta, SVP and president of Lilly International, will retire at the end of 2021, following more than three decades of service to the company. Ilya Yuffa, the current SVP and president of Lilly Bio-Medicines, will succeed Zulueta, having previously served as VP of U.S. diabetes for Lilly USA.

Mike Mason will continue to serve as SVP and president of Lilly Diabetes with responsibilities for the company’s launched products and Phase 3 portfolio of diabetes therapies.

“As we prepare for an exciting period of growth and the potential launch of new breakthrough medicines over the next few years, these leadership and organizational changes will allow us to realize the many opportunities we have to improve the lives of people around the world,” Lilly chairman & CEO David A. Ricks said in the release. “Anne, Jake and Patrik’s extensive experience will bring the focus and agility necessary to lead the growth of our existing medicines and the global introduction of Lilly’s late-stage pipeline for the benefit of patients across a diverse set of medical conditions.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co., Lilly Immunology, Lilly Neuroscience, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS